Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis

Journal of Dermatological Science

Volumn 45, Issue 2, 2007, Pages 87-92

  Wilkinson, Jonathan D ^a   Williamson, Elizabeth M ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoids; Keratinocyte proliferation; Psoriasis

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENOSINE TRIPHOSPHATE; BML 190; CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOL; DEXANABINOL; DRONABINOL; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANALGESICS, NON-NARCOTIC; CELL DIVISION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KERATINOCYTES; PSORIASIS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TETRAHYDROCANNABINOL;

EID: 33846186042     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2006.10.009     Document Type: Article

References (19)

1. Bowcock A.M., and Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5 9 (2005) 699-711 review. Erratum in: Nat Rev Immunol 2005 October;5(10):826
2. Krueger J.G., and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2 (2005) ii30-ii36 review
3. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5 5 (2005) 400-411 review
4. Kogan N.W. Cannabinoids and cancer. Mini Rev Med Chem 5 10 (2005) 941-952 review
5. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 74 4 (2003) 486-496 Epub July 1, 2003, review
6. Klein T.W., Newton C., Larsen K., Chou J., Perkins I., Lu L., et al. Cannabinoid receptors and T helper cells. J Neuroimmunol 147 1-2 (2004) 91-94
7. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 1 (2003) 43-50
8. Maccarrone M., Di Rienzo M., Battista N., Gasperi V., Guerrieri P., Rossi A., et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278 36 (2003) 33896-33903
9. Mechoulam R., Parker L.A., and Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42 11 Suppl (2002) 11S-19S review
10. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 13 (1990) 1107-1112
11. Racher A. In: Doyle A., and Griffiths J. (Eds). Laboratory procedures in biotechnology (1998), John Wiley & Sons, NY
12. Stanely P.E., and Williams S.G. Use of the liquid scintillation spectrometer for determining adenosine triphosphate by the luciferase enzyme. Anal Biochem 29 (1969) 381-392
13. Hayakawa K., Mishima K., Abe K., et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 15 15 (2004) 2381-2385
14. Vaccani A., Massi P., Colombo A., Rubino T., and Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144 8 (2005) 1032-1036
15. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2005 November 27.
16. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 77 14 (2005) 1674-1684 review
17. Kuenzli S., and Saurat J.H. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr Drug Targets Inflamm Allergy 3 2 (2004) 205-211 review
18. Bhagavathula N., Nerusu K.C., Lal A., et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 122 1 (2004) 130-139
19. Ellis C.N., Varani J., Fisher G.J., Zeigler M.E., Pershadsingh H.A., Benson S.C., et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136 5 (2000) 609-616